With a market capitalization (market cap) of $1.75B — a measure of how much the company is worth — Generate Biomedicines, Inc. ranks #2,136 among the 2,510 companies tracked, and 276th in Healthcare as of October 2, 2026. Shares trade at $13.69, down 0.80% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Not in this snapshot
Not in this snapshot
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 2, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $1.76B | — | $13.69 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.75B as of October 2, 2026.
Generate Biomedicines, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $13.69 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.76B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 50,088,504 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $685.71M. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 2, 2026, Generate Biomedicines, Inc. (GENB) is worth $1.75B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Generate Biomedicines, Inc.’s book equity is about $-623.2M. Market cap is the market value of the outstanding shares. As of October 2, 2026, its market cap is $1.75B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Generate Biomedicines, Inc. ranks #2,136 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #276 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Not in this snapshot
Too little price history
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2133 | EZCORP, Inc. EZPW | $1.77B | +0.47% |
| #2134 | Dime Community Bancshares, Inc. DCOM | $1.76B | +0.91% |
| #2135 | CTS Corporation CTS | $1.76B | +2.99% |
| #2137 | Central Puerto S.A. CEPU | $1.75B | -1.27% |
| #2138 | S&T Bancorp, Inc. STBA | $1.75B | +1.29% |
| #2139 | Hope Bancorp, Inc. HOPE | $1.75B | +1.33% |
Generate Biomedicines, Inc.’s ranking market cap of $1.75B comes from the same snapshot as the rest of this site, as of October 2, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 50,088,504. The historical market-cap series last observed $1.76B on October 2, 2026.
Generate Biomedicines, Inc. (GENB) shares trade at $13.69, down 0.80% on the day, as of October 2, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.